Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.1155/2015/279890 |
Resumo: | Objectives. To compare the effectiveness of TNF inhibitors (TNFi) and tocilizumab in rheumatoid arthritis (RA) treatment, according to different response criteria. Methods. We included RA patients registered in the Rheumatic Diseases Portuguese Register treated with TNFi or tocilizumab for at least 6 months, between January 2008 and July 2013. We assessed remission/low disease activity (LDA) at 6 months according to DAS28, CDAI, and SDAI, as well as Boolean ACR/EULAR remission and EULAR response rate, adjusting for measured confounders. Results. Tocilizumab-treated patients (n = 95) presented higher baseline disease activity and were less frequently naïve to biologics compared to TNFi users (n = 429). Multivariate logistic regression analysis including the propensity score for receiving tocilizumab showed that patients treated with tocilizumab were more likely to achieve remission or LDA according to DAS28 (OR = 11.0/6.2, 95% CI 5.6-21.6/3.2-12.0), CDAI (OR = 2.8/2.6, 95% CI 1.2-6.5/1.3-5.5), or SDAI (OR = 3.6/2.5, 95% CI 1.5-8.7/1.1-5.5), as well as a good EULAR response (OR = 6.4, 95% CI 3.4-12.0). However, both groups did not differ in Boolean remission (OR = 1.9, 95% CI 0.8-4.8) or good/moderate EULAR response (OR = 1.8, 95% CI 0.8-4.5). Conclusions. Compared with TNFi, tocilizumab was associated with greater likelihood of achieving DAS28, CDAI, and SDAI remission/LDA and EULAR good response. Boolean remission and EULAR good/moderate response did not differ significantly between groups. |
id |
RCAP_18606bf85c79b6ed6eb74da17504fbb7 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/21947 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patientsData from the Rheumatic Diseases Portuguese Register, Reuma.ptINTERLEUKIN-6 RECEPTOR INHIBITIONDRUG SURVIVALDOUBLE-BLINDADALIMUMABREMISSIONEFFICACYTRIALETANERCEPTINFLIXIMABSAFETYImmunology and Microbiology(all)Biochemistry, Genetics and Molecular Biology(all)Objectives. To compare the effectiveness of TNF inhibitors (TNFi) and tocilizumab in rheumatoid arthritis (RA) treatment, according to different response criteria. Methods. We included RA patients registered in the Rheumatic Diseases Portuguese Register treated with TNFi or tocilizumab for at least 6 months, between January 2008 and July 2013. We assessed remission/low disease activity (LDA) at 6 months according to DAS28, CDAI, and SDAI, as well as Boolean ACR/EULAR remission and EULAR response rate, adjusting for measured confounders. Results. Tocilizumab-treated patients (n = 95) presented higher baseline disease activity and were less frequently naïve to biologics compared to TNFi users (n = 429). Multivariate logistic regression analysis including the propensity score for receiving tocilizumab showed that patients treated with tocilizumab were more likely to achieve remission or LDA according to DAS28 (OR = 11.0/6.2, 95% CI 5.6-21.6/3.2-12.0), CDAI (OR = 2.8/2.6, 95% CI 1.2-6.5/1.3-5.5), or SDAI (OR = 3.6/2.5, 95% CI 1.5-8.7/1.1-5.5), as well as a good EULAR response (OR = 6.4, 95% CI 3.4-12.0). However, both groups did not differ in Boolean remission (OR = 1.9, 95% CI 0.8-4.8) or good/moderate EULAR response (OR = 1.8, 95% CI 0.8-4.5). Conclusions. Compared with TNFi, tocilizumab was associated with greater likelihood of achieving DAS28, CDAI, and SDAI remission/LDA and EULAR good response. Boolean remission and EULAR good/moderate response did not differ significantly between groups.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centro de Estudos de Doenças Crónicas (CEDOC)RUNRomão, Vasco C.Santos, Maria JoséPolido-Pereira, JoaquimDuarte, CátiaNero, PatríciaMiguel, CláudiaCosta, José AntónioBernardes, MiguelPimentel-Santos, Fernando M.Barcelos, FilipeCosta, Maria LúciaMelo Gomes, José AntónioPereira Da Silva, José AlbertoBranco, JaimeCanas da Silva, JoséPereira Da Silva, José AntónioFonseca, João EuricoCanhão, HelenaShi, Guixiu2017-07-13T22:01:48Z20152015-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article13application/pdfhttps://doi.org/10.1155/2015/279890eng2314-6133PURE: 2928022http://www.scopus.com/inward/record.url?scp=84929346565&partnerID=8YFLogxKhttps://doi.org/10.1155/2015/279890info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:09:07Zoai:run.unl.pt:10362/21947Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:27:03.439396Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients Data from the Rheumatic Diseases Portuguese Register, Reuma.pt |
title |
Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients |
spellingShingle |
Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients Romão, Vasco C. INTERLEUKIN-6 RECEPTOR INHIBITION DRUG SURVIVAL DOUBLE-BLIND ADALIMUMAB REMISSION EFFICACY TRIAL ETANERCEPT INFLIXIMAB SAFETY Immunology and Microbiology(all) Biochemistry, Genetics and Molecular Biology(all) |
title_short |
Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients |
title_full |
Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients |
title_fullStr |
Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients |
title_full_unstemmed |
Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients |
title_sort |
Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients |
author |
Romão, Vasco C. |
author_facet |
Romão, Vasco C. Santos, Maria José Polido-Pereira, Joaquim Duarte, Cátia Nero, Patrícia Miguel, Cláudia Costa, José António Bernardes, Miguel Pimentel-Santos, Fernando M. Barcelos, Filipe Costa, Maria Lúcia Melo Gomes, José António Pereira Da Silva, José Alberto Branco, Jaime Canas da Silva, José Pereira Da Silva, José António Fonseca, João Eurico Canhão, Helena Shi, Guixiu |
author_role |
author |
author2 |
Santos, Maria José Polido-Pereira, Joaquim Duarte, Cátia Nero, Patrícia Miguel, Cláudia Costa, José António Bernardes, Miguel Pimentel-Santos, Fernando M. Barcelos, Filipe Costa, Maria Lúcia Melo Gomes, José António Pereira Da Silva, José Alberto Branco, Jaime Canas da Silva, José Pereira Da Silva, José António Fonseca, João Eurico Canhão, Helena Shi, Guixiu |
author2_role |
author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) Centro de Estudos de Doenças Crónicas (CEDOC) RUN |
dc.contributor.author.fl_str_mv |
Romão, Vasco C. Santos, Maria José Polido-Pereira, Joaquim Duarte, Cátia Nero, Patrícia Miguel, Cláudia Costa, José António Bernardes, Miguel Pimentel-Santos, Fernando M. Barcelos, Filipe Costa, Maria Lúcia Melo Gomes, José António Pereira Da Silva, José Alberto Branco, Jaime Canas da Silva, José Pereira Da Silva, José António Fonseca, João Eurico Canhão, Helena Shi, Guixiu |
dc.subject.por.fl_str_mv |
INTERLEUKIN-6 RECEPTOR INHIBITION DRUG SURVIVAL DOUBLE-BLIND ADALIMUMAB REMISSION EFFICACY TRIAL ETANERCEPT INFLIXIMAB SAFETY Immunology and Microbiology(all) Biochemistry, Genetics and Molecular Biology(all) |
topic |
INTERLEUKIN-6 RECEPTOR INHIBITION DRUG SURVIVAL DOUBLE-BLIND ADALIMUMAB REMISSION EFFICACY TRIAL ETANERCEPT INFLIXIMAB SAFETY Immunology and Microbiology(all) Biochemistry, Genetics and Molecular Biology(all) |
description |
Objectives. To compare the effectiveness of TNF inhibitors (TNFi) and tocilizumab in rheumatoid arthritis (RA) treatment, according to different response criteria. Methods. We included RA patients registered in the Rheumatic Diseases Portuguese Register treated with TNFi or tocilizumab for at least 6 months, between January 2008 and July 2013. We assessed remission/low disease activity (LDA) at 6 months according to DAS28, CDAI, and SDAI, as well as Boolean ACR/EULAR remission and EULAR response rate, adjusting for measured confounders. Results. Tocilizumab-treated patients (n = 95) presented higher baseline disease activity and were less frequently naïve to biologics compared to TNFi users (n = 429). Multivariate logistic regression analysis including the propensity score for receiving tocilizumab showed that patients treated with tocilizumab were more likely to achieve remission or LDA according to DAS28 (OR = 11.0/6.2, 95% CI 5.6-21.6/3.2-12.0), CDAI (OR = 2.8/2.6, 95% CI 1.2-6.5/1.3-5.5), or SDAI (OR = 3.6/2.5, 95% CI 1.5-8.7/1.1-5.5), as well as a good EULAR response (OR = 6.4, 95% CI 3.4-12.0). However, both groups did not differ in Boolean remission (OR = 1.9, 95% CI 0.8-4.8) or good/moderate EULAR response (OR = 1.8, 95% CI 0.8-4.5). Conclusions. Compared with TNFi, tocilizumab was associated with greater likelihood of achieving DAS28, CDAI, and SDAI remission/LDA and EULAR good response. Boolean remission and EULAR good/moderate response did not differ significantly between groups. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015 2015-01-01T00:00:00Z 2017-07-13T22:01:48Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.1155/2015/279890 |
url |
https://doi.org/10.1155/2015/279890 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
2314-6133 PURE: 2928022 http://www.scopus.com/inward/record.url?scp=84929346565&partnerID=8YFLogxK https://doi.org/10.1155/2015/279890 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
13 application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137899847876608 |